CAD and fatty liver disease: As expected, the administration of MPs-A and CPs-D showed effective protection against alcohol-induced liver injuries in a dose-dependent manner, which tended to ameliorate hepatic steatosis indicated by reducing hepatocyte edema, inflammatory cell infiltrates and the fat droplets in liver tissue.